Clinical Trials Using Talimogene Laherparepvec

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talimogene Laherparepvec. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-19 of 19
  • Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Stage III-IV Melanoma

    This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
    Location: 19 locations

  • Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
    Location: 18 locations

  • Talimogene Laherparepvec and Radiation Therapy in Treating Patients with Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

    This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.
    Location: 7 locations

  • Study of Talimogene Laherparepvec In Children With Advanced Non-CNS Tumors

    This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection
    Location: 5 locations

  • Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab

    This is a phase 1b / 2, multicenter, open-label, basket trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, gastroesophageal cancer (GEC), melanoma, NSCLC, RCC in Part 1 Group A, and subjects with HCC with and without viral hepatitis in Part 1 Group B (viral hepatitis is only applicable in combination setting), and to evaluate the efficacy and safety of intratumoral talimogene laherparepvec in combination with systemic pembrolizumab in subjects with advanced TNBC, hormone receptor positive breast cancer, CRC, CSCC, and BCC in Part 2 Group A and subjects with HCC with and without viral hepatitis in Part 2 Group B. The objective of Part 1 is to evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors alone and in combination with systemically administered pembrolizumab for the non-HCC (Group A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab. Efficacy and safety will be evaluated in each of the five non-HCC tumor types from Group A separately. Similarly, the efficacy and safety of the combination treatment will be determined for Group B HCC subjects.
    Location: 6 locations

  • Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies, TEMPO Study

    This phase I trial studies the side effects and best dose of talimogene laherparepvec in treating patients with peritoneal surface tumors that spread from gastrointestinal cancer or ovarian cancer. Talimogene laherparepvec may actively kill tumor cells and promote the body’s immune system to attack the tumor. Talimogene laherparepvec is a drug that is an oncolytic virus, a genetically modified version of the herpes virus that is designed to reproduce in tumor tissue and stimulate the immune system to attack tumor cells.
    Location: 3 locations

  • Talimogene Laherparepvec with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

    This randomized phase II trial studies the side effects of talimogene laherparepvec and to see how well it works with or without hypofractionated radiation therapy in treating patients with skin melanoma, Merkel cell carcinoma, or other solid tumors that have spread to places not suitable for surgical removal. Drugs used in the immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if giving talimogene laherparepvec with or without hypofractionated radiation therapy will work better in treating patients with cutaneous melanoma, Merkel cell carcinoma, or solid tumors.
    Location: 3 locations

  • Talimogene laherparepvec before Surgery for the Treatment of High-Risk and Treatment-Naive Recurrent Melanoma

    The phase II trial investigates a viral therapy called talimogene laherparepvec to see how well it works as a first step to shrink a tumor before the main treatment (surgical removal of the tumor) in patients with melanoma that has come back after a period of treatment (recurrent). Talimogene laherparepvec is a modified herpes virus designed to enhance the immune system to destroy melanoma cells. The information learned from this study may help researchers to improve currently poor outcomes associated with early intervention for melanoma care.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

    This phase I trial studies the side effects and how well talimogene laherparepvec and panitumumab work in treating patients with squamous cell carcinoma of the skin that has spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic). Talimogene laherparepvec is a type of vaccine made from a gene-modified virus that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and panitumumab may work better in treating patients with squamous cell carcinoma of the skin compared to panitumumab alone.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)

    This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable / metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting. Subjects will be treated with talimogene laherparepvec and pembrolizumab until confirmed complete response, disappearance of all injectable lesions, documented confirmed disease progression per modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST), intolerance of study treatment, or 102 weeks from the first dose of talimogene laherparepvec and / or pembrolizumab, whichever occurs first.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • A Modified Virus (Talimogene Laherparepvec) in Treating Patients with Locally Advanced Cutaneous Angiosarcoma

    This phase II trial studies how well talimogene laherparepvec works in treating patients with cutaneous angiosarcoma that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Talimogene laherparepvec is form of modified herpes simplex virus type-1 (the ‘cold sore’ virus) that can destroy tumor cells while leaving normal cells alone. The virus’ genes are modified in a laboratory so that it produces a protein called human granulocyte macrophage colony-stimulating factor (GM-CSF) and multiplies and grows in tumor cells. Human GM-CSF is normally produced by various cells within the body and is used as a medicine to treat patients with white blood cell counts that are too low. This modified herpes simplex virus type-1 is not designed to change any genes, but instead may kill tumor cells directly, as well as stimulate the immune system to kill tumor cells throughout the body.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Talimogene Laherparepvec in Treating Patients with Cutaneous Squamous Cell Cancer

    This phase II trial studies how well talimogene laherparepvec works in treating patients with cutaneous squamous cell cancer. Talimogene laherparepvec produces a protein that may act on tumor cells and stimulates the immune system to destroy tumor cells.
    Location: Banner University Medical Center - Tucson, Tucson, Arizona

  • Nivolumab and Intrapleural T-VEC in Treating Patients with Malignant Pleural Effusion

    This phase Ib / II trial studies the side effects of directly infusing talimogene laherparepvec (T-VEC) to the pleural place (intrapleural) and, how well it works with nivolumab in treating patients with malignant pleural effusion. T-VEC is a modified herpes simplex virus type-1 (the ‘cold sore’ virus), which infects and kills tumor cells without harming normal cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving intrapleural T-VEC and nivolumab may work better in treating patients with malignant pleural effusion.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Talimogene Laherparepvec with Paclitaxel or Endocrine Therapy in Treating Participants with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer

    This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with paclitaxel or endocrine therapy in treating participants with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body, cannot be removed by surgery, or has come back after. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with paclitaxel or endocrine therapy may work better in treating participants with HER2-negative breast cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Locally Advanced or Metastatic Rectal Cancer

    This phase I trial studies the best dose and side effects of talimogene laherparepvec in combination with 5-fluorouracil, leucovorin, oxaliplatin, capecitabine, and chemoradiation before surgery in treating patients with rectal cancer that has spread from where it started to nearby tissue and lymph nodes. Drugs used in immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Drugs used in chemotherapy, such as 5-fluorouracil, leucovorin, oxaliplatin, and capecitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving talimogene laherparepvec, 5-fluorouracil, leucovorin, oxaliplatin, and capecitabine and chemoradiation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Talimogene Laherparepvec in Treating Patients with Locally Advanced, Metastatic, or Refractory Pancreatic Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of talimogene laherparepvec in treating patients with pancreatic cancer that cannot be removed by surgery and has spread from where it started to nearby tissue, lymph nodes (locally advanced), or to other places in the body (metastatic), or that does not respond to treatment (refractory). Talimogene laherparepvec may help infect and kill tumor cells and activate the body’s own immune cells to destroy the tumor cells throughout the body.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with sarcoma that has spread to other places in the body. Talimogene laherparepvec may cause tumor cell death directly in the area of tumor that it is injected into and help the immune system to recognize and destroy tumor cells present at other sites in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with sarcoma.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Ipilimumab, Nivolumab, and Talimogene Laherparepvec before Surgery in Treating Participants with Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer

    This phase I trial studies talimogene laherparepvec given together with ipilimumab and nivolumab before surgery in patients with triple-negative or estrogen receptor positive, HER2 negative localized breast cancer. Ipilimumab and Nivolumab are immune checkpoint inhibitors that enhance immune response towards cancer cells. Talimogene laherparepvec is a modifies human herpes virus 1 that is an oncolytic virus targeting cancer cells and makes tumor microenvironment more immunogenic to promote immune response against cancer. This study will assess the safety and efficacy of talimogene laherparepvec, ipilimumab, and nivolumab, and provide an insight for further improvement of immunotherapy in breast cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

    Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
    Location: 2 locations